Spots Global Cancer Trial Database for burkitt lymphoma

Every month we try and update this database with for burkitt lymphoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Safety Study of SGN-CD19A for Leukemia and Lymphoma	NCT01786096	Burkitt Lymphom... Precursor B-cel...	SGN-CD19A	1 Year -	Seagen Inc.
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	NCT04739813	Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom...	obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT	NCT03810196	Acute Leukemia Acute Myeloid L... Myelodysplastic... Acute Lymphobla... Mixed Lineage L... Lymphoblastic L... Burkitt Lymphom... Juvenile Myelom...	CliniMACS Cell ...	- 25 Years	Children's Hospital of Philadelphia
Recommendations for the Treatment of Children With Burkitt's Lymphoma	NCT04425421	Burkitt Lymphom...	OBSERVATIONAL	- 18 Years	French Africa Pediatric Oncology Group
A Safety Study of SGN-CD19A for B-Cell Lymphoma	NCT01786135	Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel...	SGN-CD19A	12 Years -	Seagen Inc.
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	NCT01947140	Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym...	Pralatrexate Romidepsin	18 Years -	Columbia University
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine	NCT06060782	Burkitt Lymphom... Lymphoblastic L... Acute Lymphobla...	Thiotepa, cyclo...	18 Years - 65 Years	Fifth Affiliated Hospital, Sun Yat-Sen University
Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma	NCT00126191	Burkitt Lymphom... Non-Hodgkins Ly... Atypical Burkit...	Rituximab Cyclophosphamid... Doxorubicin Vincristine Methotrexate Leucovorin Ifosfamide Etoposide Cytarabine Mesna	18 Years -	Dana-Farber Cancer Institute
Pilot Protocol for the Treatment of Patients With Small Non-Cleaved and Diffuse Large Cell Lymphomas	NCT00001237	Burkitt Lymphom... Lymphoma, Large... Lymphoma, Small...	granulocyte-mac...	-	National Institutes of Health Clinical Center (CC)
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma	NCT01290120	Burkitt Lymphom... B-ALL	Chemotherapy-Ri...	15 Years -	Northern Italy Leukemia Group
A Safety Study of SGN-CD19A for B-Cell Lymphoma	NCT01786135	Burkitt Lymphom... Lymphoma, Folli... Lymphoma, Large... Lymphoma, Mantl... Precursor B-cel...	SGN-CD19A	12 Years -	Seagen Inc.
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies	NCT01947140	Lymphoid Malign... Multiple Myelom... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym...	Pralatrexate Romidepsin	18 Years -	Columbia University
Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment	NCT03677128	Burkitt Lymphom... Retinoblastoma Diffuse Large B...	mNavigator	-	Duke University
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma	NCT03223610	Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom...	Venetoclax Ibrutinib Prednisone Obinutuzumab Revlimid (lenal...	18 Years -	National Institutes of Health Clinical Center (CC)
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)	NCT06395103	B-cell Acute Ly... Diffuse Large B... Burkitt Lymphom... Neuroblastoma Ewing Sarcoma	Zilovertamab ve...	6 Months - 25 Years	Merck Sharp & Dohme LLC
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes	NCT02134262	Relapsed or Ref...	Cyclophosphamid... Dose Level -1 Dose Level 1 Dose Level 2 Dose Level 3	20 Years - 70 Years	Jichi Medical University
Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14.	NCT05049473	Mature B-Cell L... Burkitt Lymphom... Unclassifiable ...	Rituximab Methotrexate Dexamethasone Iphosphamid Vincristine Etoposide Cytarabine Cyclophosphamid... Doxorubicin Vindesine Cytarabine Methotrexate Hydrocortisone Prednisone	18 Years -	PETHEMA Foundation
Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM)	NCT01196520	Lymphoma, Non-H... Malaria Herpesvirus 4, ...		- 15 Years	National Institutes of Health Clinical Center (CC)
Recommendations for the Treatment of Children With Burkitt's Lymphoma	NCT04425421	Burkitt Lymphom...	OBSERVATIONAL	- 18 Years	French Africa Pediatric Oncology Group
A Safety Study of SGN-CD19A for Leukemia and Lymphoma	NCT01786096	Burkitt Lymphom... Precursor B-cel...	SGN-CD19A	1 Year -	Seagen Inc.
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders	NCT03314974	Acute Leukemia Acute Myeloid L... Acute Lymphobla... Lymphoma Chronic Myeloge... Plasma Cell Leu... Myeloproliferat... Myelofibrosis Myelodysplasia Refractory Anem... High Risk Anemi... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Diffuse Large C... Lymphoblastic L... Burkitt Lymphom... High Grade Non-... Multiple Myelom... Juvenile Myelom... Biphenotypic/Un... MRD Positive Le... Natural Killer ... Acquired Bone M...	HSCT with TBI R... HSCT with Non-T...	- 60 Years	Masonic Cancer Center, University of Minnesota
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)	NCT06395103	B-cell Acute Ly... Diffuse Large B... Burkitt Lymphom... Neuroblastoma Ewing Sarcoma	Zilovertamab ve...	6 Months - 25 Years	Merck Sharp & Dohme LLC
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies	NCT02991898	Acute Lymphobla... Burkitt Lymphom... Natural Killer ... Chronic Myeloge... Myelodysplastic... Large-cell Lymp... Chronic Lymphoc... Small Lymphocyt... Marginal Zone B... Follicular Lymp... Lymphoplasmacyt... Mantle-Cell Lym... Prolymphocytic ... Hodgkin Lymphom... Multiple Myelom... Acute Myelogeno... Biphenotypic Le... Undifferentiate...	Infusion of Tre...	18 Years - 75 Years	Masonic Cancer Center, University of Minnesota
LMBA02 Protocol for Patients With a Burkitt Lymphoma	NCT00180882	Burkitt Lymphom...	rituximab	18 Years -	Gustave Roussy, Cancer Campus, Grand Paris
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma	NCT05020392	Diffuse Large B... Burkitt Lymphom... Follicular Lymp... Chronic Lymphoc... Mantle Cell Lym...	BTK inhibitor+ ... Fludarabine-bas...	18 Years - 70 Years	Wuhan Union Hospital, China
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)	NCT03833180	Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac...	Zilovertamab ve...	18 Years -	VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas	NCT02247609	B-cell Lymphoma...	Anti-CD19 CAR T...	18 Years -	Peking University
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma	NCT04739813	Lymphoma Non-Hodgkin Lym... Diffuse Large B... Burkitt Lymphom...	obinutuzumab prednisone Revlimid Polatuzumab ibrutinib venetoclax	18 Years - 120 Years	National Institutes of Health Clinical Center (CC)
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas	NCT06340737	Follicular Lymp... Mantle Cell Lym... Hairy Cell Leuk... Lymphoplasmacyt... Burkitt Lymphom... Marginal Zone L... Waldenstrom Mac...	CD22CART Infusi...	18 Years -	Stanford University
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL	NCT02393157	Non-Hodgkin Lym... Burkitt Lymphom... Diffuse Large B... Primary Mediast... CD20+ Lymphobla... Follicular Lymp...	Obinutuzumab Liposomal ARA-C Ifosfamide Carboplatin Etoposide	3 Years - 31 Years	New York Medical College
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)	NCT03833180	Chronic Lymphoc... Mantle Cell Lym... Follicular Lymp... Marginal Zone L... Diffuse Large B... Richter Transfo... Burkitt Lymphom... Lymphoplasmacyt... T-cell Non-Hodg... Acute Lymphoid ... Acute Myeloid L... Waldenstrom Mac...	Zilovertamab ve...	18 Years -	VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	NCT03298828	Acute Lymphobla... Burkitt Lymphom...	CD19 CAR and PD... CD19 CAR T-cell...	- 70 Years	Third Military Medical University
Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas	NCT05565417	Non Small Cell ... Head and Neck S... Triple Negative... Cutaneous Squam... Hormone Recepto... Small Bowel Can... Esophageal Canc... Colorectal Canc... Diffuse Large B... Hodgkin Lymphom... Burkitt Lymphom... Follicular Lymp...	IMT-009 Fruquintinib	18 Years -	Immunitas Therapeutics
A Phase I Trial of AZD3965 in Patients With Advanced Cancer	NCT01791595	Adult Solid Tum... Diffuse Large B... Burkitt Lymphom...	AZD3965 AZD3965 AZD3965 AZD3965 AZD3965 AZD3965 AZD3965	18 Years -	Cancer Research UK
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma	NCT01290120	Burkitt Lymphom... B-ALL	Chemotherapy-Ri...	15 Years -	Northern Italy Leukemia Group
CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma	NCT03298828	Acute Lymphobla... Burkitt Lymphom...	CD19 CAR and PD... CD19 CAR T-cell...	- 70 Years	Third Military Medical University
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL	NCT02393157	Non-Hodgkin Lym... Burkitt Lymphom... Diffuse Large B... Primary Mediast... CD20+ Lymphobla... Follicular Lymp...	Obinutuzumab Liposomal ARA-C Ifosfamide Carboplatin Etoposide	3 Years - 31 Years	New York Medical College
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma	NCT01092182	Burkitt Lymphom... Diffuse Large B... Plasmablastic L...	EPOCH-R EPOCH-RR	18 Years -	National Institutes of Health Clinical Center (CC)
GastroIntestinal Cancer in Children and Adolescents	NCT05693519	Gastrointestina... Colorectal Canc... Gastric Cancer Hepatoblastoma Hepatocellular ... Burkitt Lymphom... Neuroendocrine ...		0 Years - 24 Years	Leiden University Medical Center
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma	NCT00077493	Leukemia Lymphoma	BL22 immunotoxi... antibody-drug c... immunotoxin the... monoclonal anti...	6 Months - 24 Years	MedImmune LLC
Immune Responses to COVID-19 Vaccination in Lymphoma Patients	NCT04858568	Classical Hodgk... Diffuse Large B... Primary Mediast... High-grade B-ce... Burkitt Lymphom... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Lymphoplasmacyt... Nodular Lymphoc... Peripheral T-ce...		18 Years -	University Hospital Southampton NHS Foundation Trust
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies	NCT05990465	Non Hodgkin Lym... Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Burkitt Lymphom...	Pirtobrutinib LV20.19 CAR T c...	18 Years - 81 Years	Medical College of Wisconsin
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas	NCT01793233	Anaplastic Larg... Burkitt Lymphom... Diffuse Large B... Hodgkin Lymphom... Lymphoma	Laboratory Biom... Questionnaire A...	- 29 Years	Children's Oncology Group
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda	NCT03864419	Burkitt Lymphom... KSHV-associated... Diffuse Large B...	Rituximab and H... Cyclophosphamid... Vincristine Methotrexate Doxorubicin Doxorubicin Hyd... Prednisone Etoposide Rituximab	2 Years -	Fred Hutchinson Cancer Center
Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies	NCT02483000	Burkitt Lymphom... CD20-Positive N... Diffuse Large B... Indolent Non-Ho... Mantle Cell Lym... Recurrent B-Cel... Refractory Matu...	Anti-CD20 B9E9 ... Autologous Hema... Carmustine Clearing Agent Cytarabine Etoposide Indium In 111-D... Laboratory Biom... Melphalan Peripheral Bloo... Pharmacological... Yttrium Y 90-DO...	18 Years -	Fred Hutchinson Cancer Center
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	NCT04545762	Refractory Non-... Burkitt Lymphom... Mantle Cell Lym... Follicular Lymp... Lymphoplasmacyt... Primary Mediast... Diffuse Large B... Small Lymphocyt... Transformed Lym...	Fludarabine Cyclophosphamid... anti-CD19 CAR-T...	18 Years -	University of California, San Francisco
Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma	NCT00849654	B-Cell Lymphoma B-Cell Leukemia	PCI-32765	18 Years -	Pharmacyclics LLC.
Coproporphyrine Isomers and Methotrexate Elimination	NCT00822432	Central Nervous... Lymphoma, Large... Precursor B-Cel... Burkitt Lymphom...		18 Years -	Assistance Publique - Hôpitaux de Paris
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	NCT04491370	B-cell Lymphoma Burkitt Lymphom... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Transformed Non... Richter Syndrom... Hodgkin Lymphom...	Polatuzumab ved...	12 Years - 70 Years	New York Medical College
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma	NCT01363128	Acute Lymphobla... Adult Acute Lym... Burkitt Leukemi... Burkitt Lymphom... CD20 Positive Childhood Acute... Lymphoblastic L...	Cyclophosphamid... Cytarabine Dexamethasone Doxorubicin Hyd... Laboratory Biom... Methotrexate Ofatumumab Vincristine Sul...	-	M.D. Anderson Cancer Center
Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma	NCT01943682	Acute Myeloid L... Acute Lymphobla... Burkitt Lymphom... Diffuse Large C... Gray Zone Lymph... Lymphoblastic L... Anaplastic Larg... Hodgkin Lymphom...	CPX-351	12 Months - 30 Years	Children's Hospital Medical Center, Cincinnati
MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	NCT05794880	Leukemia Acute Myeloid L... Myelodysplasia Acute Lymphobla... Chronic Myeloge... Chronic Myeloge... Chronic Myeloge... Biphenotypic Ac... Lymphoblastic L... Burkitt Lymphom... Burkitt Leukemi... Lymphoma After ... Other Malignant...	Magnetic-Activa...	0 Years - 25 Years	Medical College of Wisconsin
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas	NCT05389423	Diffuse Large C... Non-Hodgkin Lym... Burkitt Lymphom... Plasmablastic L... B-Cell Neoplasm	Vincristine Prednisone Doxorubicin Etoposide Pomalidomide Cyclophosphamid... Rituximab	18 Years -	National Institutes of Health Clinical Center (CC)
Pegylated Liposomal Doxorubicin (Doxil) With Rituximab in Relapsed AIDS-Related Non-Hodgkin's Lymphomas	NCT00183976	Non-Hodgkin's L... Burkitt Lymphom... Primary Effusio...	Pegylated Lipos...	18 Years -	University of Southern California
Long-term Follow-up Study of Patients Receiving CAR-T Cells	NCT03375619	Chronic Lymphoc... Lymphomas Non-H... Lymphoma, Small... Mantle Cell Lym... Central Nervous... Diffuse Large B... Follicular Lymp... Burkitt Lymphom... Multiple Myelom...	Long-Term Follo...	18 Years - 80 Years	Medical College of Wisconsin
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma	NCT04491370	B-cell Lymphoma Burkitt Lymphom... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Transformed Non... Richter Syndrom... Hodgkin Lymphom...	Polatuzumab ved...	12 Years - 70 Years	New York Medical College
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy	NCT00891137	Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic...	human myeloid p...	12 Years - 65 Years	Cellerant Therapeutics
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	NCT02362035	Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk...	Acalabrutinib Pembrolizumab	18 Years -	Acerta Pharma BV
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas	NCT01793233	Anaplastic Larg... Burkitt Lymphom... Diffuse Large B... Hodgkin Lymphom... Lymphoma	Laboratory Biom... Questionnaire A...	- 29 Years	Children's Oncology Group
Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases	NCT00309842	Acute Myeloid L... Acute Lymphocyt... Chronic Myeloge... Myelofibrosis MDS Refractory Anem... Chronic Lymphoc... Prolymphocytic ... Non-Hodgkin's L... Leukemia Lymphoma Multiple Myelom... Myelodysplastic...	filgrastim cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... total-body irra...	- 55 Years	Masonic Cancer Center, University of Minnesota
A Feasibility Study of Gallium-68 Citrate PET to Detect Aberrant MYC Proto-Oncogene, BHLH Transcription Factor (MYC) Protein Expression in Diffuse Large B-Cell Lymphoma	NCT02776891	Lymphoma, Large... Burkitt Lymphom...	Gallium citrate	18 Years -	University of California, San Francisco
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies	NCT01998035	Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym...	Romidepsin Oral 5-Azacitid...	18 Years -	Columbia University
A Phase I Study of Alisertib + R-EPOCH for Treatment of Myc-Positive Aggressive B-cell Lymphomas	NCT02700022	Diffuse Large B... Follicular Lymp... Burkitt Lymphom...	Alisertib	18 Years -	UNC Lineberger Comprehensive Cancer Center
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies	NCT02362035	Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk...	Acalabrutinib Pembrolizumab	18 Years -	Acerta Pharma BV
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease	NCT00719888	Acute Biphenoty... Acute Lymphobla... Acute Myeloid L... Burkitt Lymphom... Chronic Lymphoc... Chronic Myeloge... Chronic Phase C... Follicular Lymp... Lymphoblastic L... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Myelodysplastic... Myelofibrosis Non-Hodgkin Lym... Plasma Cell Mye... Prolymphocytic ... Refractory Anem... Small Lymphocyt...	Cyclophosphamid... Cyclosporine Double-Unit Umb... Fludarabine Laboratory Biom... Mycophenolate M... Total-Body Irra... Umbilical Cord ... Thiotepa	6 Months - 45 Years	Fred Hutchinson Cancer Center
Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma	NCT05020392	Diffuse Large B... Burkitt Lymphom... Follicular Lymp... Chronic Lymphoc... Mantle Cell Lym...	BTK inhibitor+ ... Fludarabine-bas...	18 Years - 70 Years	Wuhan Union Hospital, China
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma	NCT00001337	Diffuse Large B... Primary Mediast... Burkitt Lymphom... Anaplastic Larg... Gray Zone Lymph...	EPOCH Rituximab	12 Years -	National Institutes of Health Clinical Center (CC)
Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies	NCT01998035	Lymphoid Malign... Lymphoma Hodgkin Lymphom... Non-hodgkin Lym...	Romidepsin Oral 5-Azacitid...	18 Years -	Columbia University
A Phase I Trial of AZD3965 in Patients With Advanced Cancer	NCT01791595	Adult Solid Tum... Diffuse Large B... Burkitt Lymphom...	AZD3965 AZD3965 AZD3965 AZD3965 AZD3965 AZD3965 AZD3965	18 Years -	Cancer Research UK
Allo HSCT Using RIC and PTCy for Hematological Diseases	NCT05805605	Acute Myelogeno... Acute Lymphocyt... Biphenotypic Ac... Undifferentiate... Prolymphocytic ... Chronic Myeloge... Plasma Cell Leu... Myelodysplastic... Leukemia, Myelo... Myelodysplastic... Burkitt Lymphom... Relapsed T-Cell... Relapsed Chroni... Small Lymphocyt... Marginal Zone L... Follicular Lymp... Myeloproliferat... Myelofibrosis	Peripheral Bloo... Allopurinol 300... Fludarabine Cyclophosphamid... Bone Marrow Cel... Total Body Irra... Sirolimus Pill Mycophenolate M...	- 75 Years	Masonic Cancer Center, University of Minnesota
Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine	NCT02996773	Acute Lymphobla... Acute Myelogeno... Myelodysplastic... Chronic Myeloge... Lymphoma,Non-Ho... Lymphoma, Hodgk... Lymphoma, Folli... Marginal Zone L... Large Cell Lymp... Mantle-Cell Lym... Gray Zone Lymph... Burkitt Lymphom... High Risk Undif...	Bendamustine Cyclophosphamid...	4 Years - 30 Years	University of Arizona

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: